Reuters logo
BRIEF-PCI Biotech: initial results from fimaVACC Phase I ​
September 12, 2017 / 6:14 AM / 9 days ago

BRIEF-PCI Biotech: initial results from fimaVACC Phase I ​

Sept 12 (Reuters) - PCI BIOTECH HOLDING ASA

* ‍FIRST IMMUNE RESPONSE RESULTS FROM FIMAVACC PHASE I STUDY INDICATE ENHANCED OVERALL T-CELL RESPONSES AT TOLERABLE DOSE LEVELS.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below